Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITE: Neuroinflammation and BBB Breakdown in Intracerebral Hemorrhage
NCT07583147Phase 2Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DPA-714, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: 18F-DPA-714 PET radiotracer uptake according to functional outcome at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
DPA-714
Beyond the preview
Go deeper on NCT07583147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583147.